Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Releases Quarterly Earnings Results, Misses Expectations By $0.08 EPS

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) announced its earnings results on Tuesday. The company reported $0.23 EPS for the quarter, missing the consensus estimate of $0.31 by ($0.08), Zacks reports. The company had revenue of $180.85 million for the quarter, compared to the consensus estimate of $166.64 million. Kiniksa Pharmaceuticals International had a return on equity of 7.46% and a net margin of 6.01%.The business’s quarterly revenue was up 61.2% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.18) EPS.

Kiniksa Pharmaceuticals International Trading Up 1.2%

Shares of Kiniksa Pharmaceuticals International stock opened at $37.47 on Tuesday. The company has a 50 day moving average of $37.00 and a 200-day moving average of $31.33. Kiniksa Pharmaceuticals International has a 1-year low of $17.82 and a 1-year high of $42.05. The company has a market cap of $2.78 billion, a PE ratio of 83.27 and a beta of 0.16.

Wall Street Analyst Weigh In

Several brokerages recently commented on KNSA. Wedbush reaffirmed an “outperform” rating and set a $48.00 target price (up previously from $44.00) on shares of Kiniksa Pharmaceuticals International in a report on Tuesday, October 28th. Zacks Research downgraded shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th. The Goldman Sachs Group boosted their price objective on shares of Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Jefferies Financial Group boosted their price objective on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a “buy” rating in a report on Tuesday, July 29th. Finally, Citigroup boosted their price objective on shares of Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the company a “buy” rating in a report on Friday, October 17th. Seven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, Kiniksa Pharmaceuticals International has an average rating of “Moderate Buy” and an average price target of $50.29.

Insider Activity

In other news, COO Eben Tessari sold 12,368 shares of the company’s stock in a transaction that occurred on Tuesday, October 14th. The shares were sold at an average price of $37.67, for a total transaction of $465,902.56. Following the completion of the sale, the chief operating officer owned 28,684 shares of the company’s stock, valued at approximately $1,080,526.28. This represents a 30.13% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Sanj K. Patel sold 97,390 shares of the company’s stock in a transaction that occurred on Wednesday, October 22nd. The stock was sold at an average price of $38.83, for a total transaction of $3,781,653.70. Following the sale, the chief executive officer directly owned 111,794 shares of the company’s stock, valued at approximately $4,340,961.02. This trade represents a 46.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 730,895 shares of company stock worth $26,574,480. Insiders own 53.48% of the company’s stock.

Institutional Trading of Kiniksa Pharmaceuticals International

Institutional investors and hedge funds have recently made changes to their positions in the company. EverSource Wealth Advisors LLC increased its position in Kiniksa Pharmaceuticals International by 140.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after purchasing an additional 532 shares in the last quarter. Osaic Holdings Inc. acquired a new position in Kiniksa Pharmaceuticals International during the 2nd quarter worth approximately $31,000. Quantbot Technologies LP acquired a new position in Kiniksa Pharmaceuticals International during the 2nd quarter worth approximately $43,000. Creative Planning acquired a new position in Kiniksa Pharmaceuticals International during the 2nd quarter worth approximately $358,000. Finally, Lazard Asset Management LLC increased its position in Kiniksa Pharmaceuticals International by 428.8% during the 2nd quarter. Lazard Asset Management LLC now owns 15,181 shares of the company’s stock worth $420,000 after purchasing an additional 12,310 shares in the last quarter. Institutional investors own 53.95% of the company’s stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.